NHS, Mounjaro
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
God knows what volume they’re actually selling. And who knows? You’re just taking it,” one expert told The Post.
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded ...
While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...
Ozempic and other diabetes-weight loss drugs have been linked to at least 162 deaths and 10,000 cases involving “serious” ...
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...
Nearly 250,000 people in England could be taking Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro within three years ...
The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...
Eli Lilly (NYSE:LLY) investing $4.5B to create Lilly Med Foundry, with goal of faster drug pipeline and scaling molecules to medicines. Stock outlook mixed.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback